Wall Street Analysts Think Relay Therapeutics (RLAY) Could Surge 86.05%: Read This Before Placing a Bet
The consensus price target hints at an 86.1% upside potential for Relay Therapeutics (RLAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why Relay Therapeutics, Inc. (RLAY) is a Great Momentum Stock to Buy
Does Relay Therapeutics, Inc. (RLAY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Believe Relay Therapeutics (RLAY) Could Rally 116.91%: Here's is How to Trade
The mean of analysts' price targets for Relay Therapeutics (RLAY) points to an 116.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Relay Therapeutics, Inc. (RLAY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Relay Therapeutics, Inc. (NASDAQ:RLAY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants Sanjiv Patel - CEO, President & Director Donald Bergstrom - President of Research & Development Peter Rahmer - Chief Corporate Development Officer Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone, and welcome to Morgan Stanley Global Healthcare Conference. I'm Sean Laaman, Head of U.S. SMID Cap Biotech Equity Research here at the firm.
Relay Therapeutics (RLAY) Upgraded to Buy: What Does It Mean for the Stock?
Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Beats Revenue Estimates
Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.69 per share a year ago.
Relay Therapeutics: What's Next For H2 2025?
Upgraded Relay Therapeutics to a buy after an unjustified valuation decline, maintaining cautious optimism. Recent ASCO data and quarterly updates provide new insights into the evolving investment thesis for RLAY. Pipeline progress and financial health remain central to the company's long-term value proposition and risk profile.
What Makes Relay Therapeutics (RLAY) a New Buy Stock
Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Relay Therapeutics: Trying To Find That Right Price
Relay Therapeutics' pipeline has shifted, with the FGFR2 inhibitor lirafugratinib outlicensed to Elevar, bringing in cash and royalties, but losing global rights. RLY-2608, a PI3K-alpha inhibitor, shows promise in breast cancer trials, with plans for a phase 3 trial and potential in other cancers. Financially, RLAY holds $124.3M in cash and $657M in investments, with a cash runway into mid-2026, bolstered by recent cost-saving measures.
Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY)
The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade
Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY)
Relay Therapeutics (RLAY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
